Alignment Healthcare, Inc. (NASDAQ:ALHC – Get Free Report) CEO John Kao sold 118,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $17.48, for a total value of $2,062,640.00. Following the transaction, the chief executive officer directly owned 2,354,641 shares in the company, valued at approximately $41,159,124.68. This represents a 4.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Alignment Healthcare Stock Up 1.0%
Shares of ALHC opened at $17.51 on Tuesday. The company has a market cap of $3.58 billion, a PE ratio of -1,749.25, a P/E/G ratio of 2.54 and a beta of 1.19. The business has a fifty day moving average of $20.37 and a 200 day moving average of $18.83. Alignment Healthcare, Inc. has a 52-week low of $11.63 and a 52-week high of $23.87. The company has a quick ratio of 1.71, a current ratio of 1.71 and a debt-to-equity ratio of 1.80.
Alignment Healthcare (NASDAQ:ALHC – Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period in the previous year, the firm earned ($0.16) earnings per share. Alignment Healthcare’s quarterly revenue was up 44.4% compared to the same quarter last year. On average, sell-side analysts expect that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.
Institutional Investors Weigh In On Alignment Healthcare
Analyst Ratings Changes
ALHC has been the topic of a number of recent analyst reports. TD Cowen increased their price objective on shares of Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Wednesday, January 21st. Robert W. Baird set a $28.00 target price on Alignment Healthcare in a research note on Friday, January 30th. Piper Sandler increased their price target on Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Finally, KeyCorp reissued an “overweight” rating and set a $28.00 price target on shares of Alignment Healthcare in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.56.
Get Our Latest Stock Report on Alignment Healthcare
About Alignment Healthcare
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
See Also
Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
